

► Patient reminder card regarding osteonecrosis of the jaw

This reminder card contains important safety information that you need to be aware of before and during treatment with Aclasta® (zoledronic acid).

Your doctor has recommended that you receive Aclasta®, which is used to treat post-menopausal women and adult men with osteoporosis or osteoporosis caused by treatment with steroids, and Paget's disease of the bone in adults. These diseases involve thinning and weakening of the bones so they may break more easily.

A side effect called osteonecrosis of the jaw (ONJ) (severe bone damage in the jaw) has been reported very rarely in patients receiving Aclasta® for osteoporosis. ONJ can also occur after stopping treatment.

It is important to try and prevent ONJ developing as it is a painful condition that can be difficult to treat. In order to reduce the risk of developing ONJ, there are some precautions you should take:

Before starting treatment:

Tell your doctor/nurse (health care professional) if you have any problems with your mouth or teeth. Your doctor may ask you to undergo a dental examination if you:

- were previously treated with a bisphosphonate
- are taking medicines called corticosteroids (such as prednisolone or dexamethasone)
- are a smoker
- have cancer
- have not had a dental check up for a long time
- have problems with your mouth or teeth

While being treated:

- You should maintain good oral hygiene, brush your teeth regularly and receive routine dental check-ups. If you wear dentures you should make sure these fit properly
- If you are under dental treatment or will undergo dental surgery (e.g. tooth extractions), inform your doctor and tell your dentist that you are being treated with Aclasta®
- Contact your doctor and dentist immediately if you experience any problems with your mouth or teeth such as loose teeth, pain or swelling, or non-healing of sores or discharge, as these could be signs of osteonecrosis of the jaw

Please read the package leaflet that comes with your medicine for further information.

Reporting of side effects

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at: <https://yellowcard.mhra.gov.uk> or search for MHRA Yellow Card in the Google Play or Apple App Store

By reporting side effects you can help provide more information on the safety of this medicine.

Artwork Proof Box:

Variation:	N001: Administrative update to educational material for Aclasta, PL04417/1703.	Technical Colours:	
Proof no:	001.0		Legend:
Date prepared:	09/03/2023		
Font size:	11.5 pt		
Fonts:	FuturaCEEF, Helvetica		
Dimensions:	148 x 210 mm		
Technical data:			
SKUs:	00000000		
SZ codes:	SZ0000000000		
Item codes:	00000000		
Pharma codes:	00000000	Colours:	
Novartis data if applicable:			Pantone 541
Version:	00000000		Black:
Print Proof date:	00000000		
AQWA#:	00000000		
Production site:	00000000		
Technical num:	00000000		
Old Comp num:	00000000		



Signature Panel:

